Adult male and female standing on top of mountain, overlooking. Not actual patients.

Adult male and female standing on top of mountain, overlooking. Not actual patients.

Not actual patients.

Safety & side effects

Information you should know about HYMPAVZI

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to urticaria (hives) and pruritus (itching)). If you develop a hypersensitivity reaction during treatment with HYMPAVZI, stop using HYMPAVZI and get medical help right away.

HYMPAVZI may cause fetal harm when administered to a pregnant woman. Women who are able to bear children are advised to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

The most common side effects reported in ≥3% of patients treated with HYMPAVZI were*:

Adverse Reactions (N=116)
Number of Patients, n (%)
Injection site reaction
11 (9)
Headache
8 (7)
Pruritus (itching)
4 (3)

HYMPAVZI may cause serious side effects, including:

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Doctor icon with stethoscope
You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider’s instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.
Meet real patients
Next